Risk adjusted net present value: What is the current valuation of Forte Biosciences’s FB-102?

FB-102 is a monoclonal antibody commercialized by Forte Biosciences, with a leading Phase I program in Celiac Disease.

Steve Davis leaves Acadia, replaced by Bristol Myers alum; Former J&J exec to lead R&D at Novavax

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

September 28, 2024

AI and imaging advances revolutionize multiple sclerosis diagnosis

A study in Translational Vision Science & Technology reveals that integrating AI with IR-SLO and OCT imaging improves the automated diagnosis and classification of multiple

July 22, 2024

Aventa Genomics Announces Launch of Aventa FusionPlus, the First 3D Genomics Clinical Test for Patients with Solid Cancers

Aventa™ Genomics, LLC, a clinical laboratory established as a joint venture between Arima Genomics, Inc. and Protean BioDiagnostics Inc., today announced the launch of Aventa

October 4, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.